SummaryRMgm-135
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 15659064 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | T. Ishino, M. Yuda |
Name Group/Department | School of Medicine |
Name Institute | Mie University |
City | Mie |
Country | Japan |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-135 |
Principal name | spect2(-)1; spect2(-)2 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Normal numbers of midgut- and salivary gland sporozoites are formed. Sporozoites have a strongly reduced infectivity to rats after intravenous injection of sprozoites and strongly reduced numbers of exoerythrocytic forms (EEFs) in frozen sections of rat livers were counted 24 h after sporozoite inoculations. |
Liver stage | Sporozoites have a strongly reduced infectivity to rats after intravenous injection of sprozoites and strongly reduced numbers of exoerythrocytic forms (EEFs) in frozen sections of rat livers were counted 24 h after sporozoite inoculations. Sporozoites formed normal numbers of EEFs in hepatoma cells (HepG2), indicating that they retain normal infection ability. Sporozoites had completely lost cell passage ability as shown in the cell-wounding assay. Cell-passage activity was estimated by the number of cells wounded by sporozoite passage, which were identified by cytosolic labelling with FITC-conjugated dextran. In Kupffer cell-depleted rats, the sporozoites had restored liver infectivity. Parasitaemia after inoculation of mutant sporozoites was remarkably increased in Kupffer-depleted rats, becoming similar to that after inoculation of wild-type sporozoites In addition, the numbers of EEFs formed in the liver were also similar between spect2-disruptants and the wild type. |
Additional remarks phenotype | Mutant/mutation Additional information Other mutants See also RMgm-138 and RMgm-139 for mutants lacking the expression of SPECT which show a comparable defect in cel traversal capacity, whereas the capabilty to invade hepatocytes is not affected. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1006300 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0408700 | ||||||||||||||||||||||||
Gene product | perforin-like protein 1 | sporozoite micronemal protein essential for cell traversal | ||||||||||||||||||||||||
Gene product: Alternative name | PPLP1; Plasmodium perforin like protein 1; Membrane attack Complex; SPECT2 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | pbdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |